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METHODS: A within trial study was designed. Survival gains
were estimated using an extraction of comparable patients from
the Saskatchewan Health Data Base. A piecewise regression
model yielded death rates adjusted on patients’ characteristics.
Resource use was collected alongside the clinical trial. Only
direct medical costs were considered. Hospital costs were calcu-
lated using French DRG costs, and the National Fee Schedule
for outpatient diagnostic procedures. All costs were in 2003
Euros. A sensitivity analysis using bootstrap was used to build a
conﬁdence interval for the Incremental Cost-Effectiveness Ratio,
and an acceptability curve. Costs and outcomes were discounted
at ﬁve percent. RESULTS: Overall mortality over the trial period
was 478 (14.4%) in the treatment group vs. 554 (16.7%) in the
placebo group (p = 0.008). Combined CV deaths and hospitali-
sations were 885 (26.7%) in the treatment group, vs. 993
(30.3%) in the placebo group (p = 0.002). The discounted gain
of survival was 3.2 weeks. The incremental cost per life year
saved was €15,382 (95% IC: €8274–€42,723). Following the
sensitivity analysis, 74% of the values of the ICER fell under a
€50,000 per life-year saved. CONCLUSIONS: In France, the
ICER compares with those of heart transplantation (€17,626)
and of rt-PAs in the prevention of thrombotic events during the
acute phase of AMI (€12,190). The main limitation of the study
is the restriction to the duration of the trial. Sub-group analysis
was not performed in the EPHESUS trial, and it was not possi-
ble to compute an ICER for severe heart failure patients, for
which one can expect a lower cost per life-year saved.
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THE ADD-ON TREATMENT WITH METOPROLOL SUCCINATE
IN PATIENTS WITH CHRONIC HEART FAILURE (CHF) LEADS
TO COST SAVINGS IN THE GERMAN HEALTH CARE
SYSTEM—A MODEL APPROACH
Hass B, Fricke FU, Kotowa W
Fricke & Pirk GmbH, Nuremberg, Germany
OBJECTIVES: The health economic impact of an additional
metoprolol succinate treat-ment (METsuc) in patients with
chronic heart failure (CHF) was analyzed for “real life” treat-
ment patterns on the basis of the MERIT-HF—Trial (Metopro-
lol CR/XL Randomized Intervention Trial in Congestive Heart
Failure). METHODS: Based on the efﬁcacy data of the MERIT-
HF, a markov model was created to simulate the effectiveness of
METsuc treatment under real-life conditions. The additional
direct costs associated with METsuc were examined in relation
to the number of fatalities and of hospitalizations avoided. The
cost analysis was conducted from the perspective of the German
Statutory Health Insurance (SHI). Base year for the cost data was
2004. Probabilities were derived from the MERIT-HF—Trial.
Missing data for this approach were assessed with the help of a
focus group with eight general practitioners and cardiologists.
Further, the number of life-years gained was calculated by using
the DEALE method (Declining Exponential Approximation of
Life Expectancy). RESULTS: For the period observed (18
months), additional METsuc treatment does not lead to addi-
tional costs for the Statutory Health Insurance (SHI) in Germany.
With the application of METsuc, costs of about 3400 EUR per
fatality and almost 1800 EUR per hospitalization could be
avoided. The life expectancy of a CHF patient is 1.51 years
higher in comparison to standard treatment alone. Univariate
sensitivity analyses were conducted to demonstrate the robust-
ness of the results. CONCLUSIONS: The additional costs for
METsuc in the outpatient sector are compensated by reduced
expenditures in the inpatient sector as well as in the ﬁeld of
ambulance transportation. On the basis of the present analysis
the treatment with metoprolol succinate represents an approach
for integrated health care under a clinical as well as under an
economical perspective.
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COST-EFFECTIVENESS OF CANDESARTAN IN GERMANY FOR
PATIENTS WITH CHRONIC HEART FAILURE
Voelkl M, Pirk O, Juenger V
Fricke & Pirk GmbH, Nuremberg, Germany
OBJECTIVES: To evaluate the cost-effectiveness (CE) of can-
desartan for patients with chronic heart failure (CHF) in
Germany based on the CHARM (Candesartan in Heart failure:
Assessment of Reduction in Mortality and Morbidity)-
programme. METHODS: Two CE-analyses were conducted:
incremental cost-per-avoided-event and incremental cost per life-
years gained. Effectiveness data were derived from the CHARM-
programme which provided data on three treatment groups with
CHF-patients: “Added” (low left ventricular ejection fraction
(LVEF <40%), “Alternative” (LVEF <40% and patients’ ACE-
inhibitor intolerance) and “Preserved” (LVEF >40%). Besides, an
“Overall” analysis was processed. All cardiovascular events
(Hospital admissions due to worsening heart failure, cardiovas-
cular deaths, and cardiovascular procedures) were extracted.
Absolute risk reduction (ARR; only ﬁrst events counted) to
prevent/delay one event was evaluated. Cost calculation was per-
formed from the perspective of the German statutory health
insurance (SHI). Base year for costing was 2004. Only direct
costs (drug, hospital, general practitioner, specialist, ambulance,
rehabilitation) were considered. Incremental costs between can-
desartan and placebo were used building a ratio with ARR.
Long-term effectiveness was estimated calculating the incremen-
tal costs per life-year gained (LYG). LYG were generated using
the DEALE (Declining Exponential Approximation of Life
Expectancy)-approximation. RESULTS: The incremental costs
to prevent/delay a cardiovascular death or a hospital admission
were €2279 (“Added”), €2763 (“Alternative”), €31,015 (“Pre-
served”) and €7717 (“Overall”). The incremental costs per life-
year gained were 47 EUR (“Added”), 131 EUR (“Alternative”),
€11,054 (“Preserved”) and €231 (“Overall”). Sensitivity analy-
ses were conducted for all treatment groups. The results were
robust to variations of costs, discounting rates and effects. CON-
CLUSIONS: With regard to the results of the treatment groups
“Added” and “Alternative”, candesartan is a cost-effective treat-
ment option for patients with low left ventricular ejection frac-
tion in Germany.
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COSTS AND OUTCOMES AFTER FIRST HEART FAILURE
HOSPITAL ADMISSION: A LONGITUDINAL STUDY USING
ADMINISTRATIVE DATABASES
Morsanutto A1, Mantovani LG2, Ros B3, De Portu S2, Spazzapan D3,
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OBJECTIVE: To assess the economic and epidemiologic impact
of CHF in Friuli Venezia Giulia (FVG) a region of approximately
1.2 million inhabitants in the north-eastern Italy. METHODS:
All residents of FVG are registered in to Regional Health Service
(RHS) database, which keeps tracks of the use of medical care
admissions and reimbursement purposes. We selected residents
of FVG who had during year 2000 a ﬁrst CHF hospital admis-
sion and we followed them up till death, or December 31, 2004.
(we a priory excluded people who during the period 1995–1999
had a previous CVD event). Mortality was investigated by col-
lecting information from Regional Citizen Register ﬁle. We
obtained information on medical costs from electronic databases
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of prescriptions, hospitalizations, visits and diagnostic examina-
tions in FVG. Direct medical costs were quantiﬁed in the per-
spective of the RHS and are expressed in Euro 2005. RESULTS:
We enrolled 2122 patients with incident CHF (mean age 78 ±
11 y.o.), 55.3% were women. The average cost person/year was
€5896, 54; 80% attributable to hospitalisations, 13.7% to drugs,
6.3% to other medical costs. A total of 1320 (62.2%) patients
died during the follow-up period. Mortality was higher in male
(p < 0.0001) and older subjects (p < 0.0001). CONLUSIONS:
CHF imposes a huge economic burden on NHS and society
because of the large number of hospitalisation and the high rate
of mortality after the ﬁrst event. Future investigations will be
conducted to asses the relationships between comorbidity, costs,
drug therapy and survival.
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IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT
ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING 
COSTS OF ANGIOTENSIN CONVERTING ENZYME
INHIBITORS (ACEIS)
Alabbadi I1, McElnay J1, Crealey G1, Scott M2, Mairs J2
1Queen’s University Belfast, Belfast, UK; 2United Hospitals Trust,
Belfast, UK
OBJECTIVE: SOJA is a structured approach to the selection of
drugs for formulary inclusion. The aim of this study was to use
a modiﬁed SOJA approach in the selection of ACEI products for
use within a health board in Northern Ireland. METHODS: The
modiﬁed SOJA approach involved three phases in sequence: an
evidence based pharmacotherapeutic evaluation of all available
ACEI drug entities, a separate safety / risk assessment analysis
of products containing agents which exceeded the pharma-
cotherapeutic threshold and ﬁnally a budgetary impact analysis.
A comprehensive literature review and expert panel judgment,
informed selection of criteria (and their relative weighting) for
the pharmacotherapeutic evaluation. The resultant criteria /
scoring system was circulated (in questionnaire format) to pre-
scribers and stakeholders for comment. Based on statistical
analysis of the latter survey results, the ﬁnal scoring system was
developed. Drug entities which exceeded the evidence threshold
score were entered into a tendering process with pharmaceutical
suppliers. Products submitted as a result of the tendering process
were sequentially entered into the second and third phases of the
modiﬁed SOJA process (safety / risk assessment; budgetary
impact analysis). RESULTS: Five drug entities (from the 11 cur-
rently available in the UK) exceeded the evidence threshold and
22 from 26 submitted product lines, containing these drug enti-
ties, satisﬁed the safety evaluation / risk assessment criteria.
Three product lines, each containing a different drug entity, were
selected for formulary inclusion as a result of the budgetary
impact analysis. The estimated annual cost savings for ACEIs as
a result of this selection (based on estimated annual usage in
Deﬁned Daily Doses) in this health board was 41%. CONCLU-
SION: The modiﬁed SOJA approach has a signiﬁcant contribu-
tion to make in containing ACEI costs while retaining the same
level of patient care.
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USE OF CONTRAST ECHOCARDIOGRAPHY: A REVIEW OF
CLINICAL DATA USING A SYSTEMATIC APPROACH
Cottrell S1, Richardson R1, Lewis S1,Yankah E1, Chambers M2
1M-TAG, A division of IMS Health Economics and Outcomes
Research, London, UK; 2GE Healthcare, Amersham, UK
OBJECTIVE: Risk assessment is important in determining the
management of patients with suspected or conﬁrmed coronary
artery disease (CAD). However, evidence supporting the clinical
impact of contrast echocardiography (CE) in this sphere is not
well known. The objective was to review and summarise the clin-
ical data for licensed and investigational applications of CE in
CAD, using systematic review methodology. METHODS: Full
publications of clinical studies of selected contrast agents were
identiﬁed through searches of electronic literature databases and
application of predeﬁned inclusion criteria. Studies were cate-
gorised and key data were extracted and tabulated for analysis.
No statistical pooling of data was undertaken due to study het-
erogeneity. RESULTS: 2275 abstracts were screened. 61 studies
met inclusion criteria and were categorised as follows: effective-
ness in image enhancement (23 studies); accuracy in the diagno-
sis of CAD, using coronary angiography as the diagnostic gold
standard (23 studies); myocardial viability assessment (16
studies); prognostic accuracy (2 studies). Using second genera-
tion contrast agents, diagnostic images were obtained in 48–98%
(median = 74%) of patients with suboptimal un-enhanced
images and several studies reported improved intra- and inter-
operator reproducibility. Reported sensitivities and speciﬁcities
for CAD diagnosis ranged from 41–100% (median = 86%) and
44–100% (median = 81%). Two studies reported that informa-
tion gained from myocardial contrast echocardiography (MCE)
provided incremental diagnostic value to that from left ventric-
ular function (LVF) assessment alone. Reported sensitivities 
and speciﬁcities of myocardial viability assessment by MCE 
for predicting LVF recovery ranged from 50–96% (median =
74%) and 44–96% (median = 83%). CONCLUSIONS: The
body of evidence suggests that effective use of contrast agents in
echocardiography extends beyond the licensed use in patients
with suboptimal baseline images. MCE is effective in the assess-
ment of myocardial perfusion in the diagnosis of CAD and the
detection of myocardial viability. Interpretation is limited by the
size of studies, lack of long-term outcomes and potential refer-
ral bias.
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CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR
OUTCOMES IN ACUTE CORONARY SYNDROME 
PATIENTS WHO UNDERGO PERCUTANEOUS 
CORONARY INTERVENTION
Wang C1, He J1, Bae JP2, McCollam PL2, Grifﬁn BT1
1Solucient, Inc, Berkeley Heights, NJ, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA
OBJECTIVES: The 2002 AHA/ACC guideline recommends
acute coronary syndrome patients who undergo percutaneous
coronary intervention (ASC-PCI) be given 300mg loading dose
(LD) of clopidogrel, but higher LD has emerged in practice. A
recent trial involving 255 patients found 600mg of clopidogrel
had better outcomes than 300mg (Patti et al, 2005). The current
study investigates whether patients treated with higher clopido-
grel LD experience better outcomes in the usual care setting.
METHODS: We followed 6,282 ACS-PCI patients in a national
hospital database with time-stamp information (1/2003–9/2004)
for 60 days upon discharge. Using the time-stamp, LD was mea-
sured as total dose within 24-hour window of peri-PCI proce-
dure, and myocardial infarction (MI) was captured from
post-procedure lab tests. Patients receiving >300mg are grouped
into high LD (HLD) (nH = 1465) and £300mg, the low LD
group (LLD) (nL = 4152). Primary endpoints (i.e., death, stroke,
repeat revascularization, and MI) plus bleeding and re-admission
were monitored. Logistic regression tested effects of LD on
events with controls for risk. RESULTS: LD ranged from 75mg
to 1275mg. The HLD group did not experience better outcome.
While 28.49% of LLD experienced an event, the rate was
44.23% for the HLD (p < 0.0001). MI rate was higher for HLD
